GRACE: diagnostics' role in EU AB resistance
This article was originally published in Clinica
The involvement of small and medium-sized companies that can help to develop bedside diagnostic tests is seen as vital in the context of a scientific network that has just been launched by the European Commission. The network's overall aim is to tackle increasing resistance to antibiotics (AB) through genomics. Entitled GRACE (Genomics to combat Resistance against Antibiotics in Community-acquired lower respiratory tract infections in Europe), the network brings together 17 academic groups from nine EU member states.